Showing results (1361-1370 of 2,182) with videos related to
Sort By:
Pageof 219
Journal of Biopharmaceutical Statistics|July 9, 2008
A safety monitoring procedure for a clinical drug development program, with application to the assessment of a novel COX-2 inhibitorKim Bolland, John Whitehead, Mary OldhamJournal of Biopharmaceutical Statistics|November 21, 2007
Optimal designs for estimating the interesting part of a dose-effect curveFrank Miller, Olivier Guilbaud, Holger DetteJournal of Biopharmaceutical Statistics|November 21, 2007
Statistical analysis for two-stage seamless design with different study endpointsShein-Chung Chow, Qingshu Lu, Siu-Keung TseJournal of Biopharmaceutical Statistics|April 23, 2009
Optimal two-stage randomized multinomial designs for Phase II oncology trialsLinda Z Sun, Cong Chen, Kamlesh PatelJournal of Biopharmaceutical Statistics|April 23, 2009
Selecting promising treatments in randomized Phase II cancer trials with an active controlYing Kuen CheungJournal of Biopharmaceutical Statistics|September 11, 2008
Estimation of lag time between onset of and death from an occult tumorHongshik Ahn, Hojin Moon, Ralph L KodellJournal of Biopharmaceutical Statistics|September 11, 2008
Proof of hazard and proof of safety in toxicological studies using simultaneous confidence intervals for differences and ratios to controlLudwig A Hothorn, Mario HaslerJournal of Biopharmaceutical Statistics|September 11, 2008
A comparison of false positive rates of peto and poly-3 methods for long-term carcinogenicity data analysis using multiple comparison adjustment method suggested by Lin and RahmanMohammad A Rahman, Karl K LinJournal of Biopharmaceutical Statistics|September 11, 2008
Statistical assessment of analytical method transferJinglin Zhong, Kathy Lee, Yi TsongJournal of Biopharmaceutical Statistics|February 13, 2009
An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerationsAnastasia Ivanova, Michael MurphyPageof 219